CompletedPhase 1Phase 2

Study to Evaluate CCS1477 in Advanced Tumours

NCT03568656

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

+18 additional locations

Save this trial

Dana-Farber Cancer InstituteBoston, Massachusetts, United States
Thomas Jefferson University, Sidney Kimmel Cancer CenterPhiladelphia, Pennsylvania, United States
Institute BergonieBordeaux, France
Hôpital Europeen Georges PompidouParis, France
Institute Gustave RoussyVillejuif, France
Netherlands Cancer Institute (NKI)Amsterdam, Netherlands
Hospital Vall d'Hebron, VHIOBarcelona, Spain
START CIOCC Hospital Universitario HMMadrid, Spain
Karolinska InstituteStockholm, Sweden
Belfast City HospitalBelfast, United Kingdom
Queen Elizabeth Hospital Cancer CentreBirmingham, United Kingdom
Cambridge University HospitalCambridge, United Kingdom
Edinburgh Cancer Centre Western General HospitalEdinburgh, United Kingdom
The Beatson West of Scotland Cancer CentreGlasgow, United Kingdom
Leicester Royal InfirmaryLeicester, United Kingdom
The Christie HospitalManchester, United Kingdom
Freeman HospitalNewcastle, United Kingdom
University Hospital SouthamptonSouthampton, United Kingdom
Royal Marsden HospitalSutton, United Kingdom